Compare PRG & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | NEO |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2008 |
| Metric | PRG | NEO |
|---|---|---|
| Price | $38.52 | $11.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $50.00 | $13.38 |
| AVG Volume (30 Days) | 365.0K | ★ 1.3M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $2,409,223,000.00 | N/A |
| Revenue This Year | $23.77 | $10.63 |
| Revenue Next Year | $7.91 | $9.73 |
| P/E Ratio | $41.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.80 | $4.72 |
| 52 Week High | $41.14 | $13.74 |
| Indicator | PRG | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 64.32 |
| Support Level | $32.30 | $7.50 |
| Resistance Level | $38.57 | $11.41 |
| Average True Range (ATR) | 1.48 | 0.57 |
| MACD | 0.13 | 0.10 |
| Stochastic Oscillator | 77.00 | 74.25 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.